Breast Cancer
Conditions
Keywords
adjuvant chemotherapy, epirubicin, cyclophosphamide, docetaxel, paclitaxel, carboplatin, trastuzumab, non-triple negative breast cancer, pertuzumab
Brief summary
This study is a randomized, single center, phase III clinical trial comparing the efficacy and safety of four cycles of epirubicin combined with cyclophosphamide followed by four cycles of docetaxel (EC\*4-T\*4) verses 6 cycles of weekly paclitaxel combined with carboplatin (PCb\*6) in the adjuvant chemotherapy of non-triple negative breast cancer patients. The study is divided in to 2 branches: PANSY-1 and PANSY-2. PANSY-1 is a study of hormone receptor (HR)-positive/human epidermal growth factor receptor-2 (HER2)-negative patients with ≥4 positive lymph node, while PANSY-2 is a study of HER2-positive patients with ≥1 positive lymph node.
Detailed description
PANSY-1 will be comparing the efficacy and safety of four cycles of epirubicin combined with cyclophosphamide followed by four cycles of docetaxel (EC-T) verses six cycles of paclitaxel combined with carboplatin (PCb). PANSY-2 will be comparing the efficacy and safety of four cycles of epirubicin combined with cyclophosphamide followed by four cycles of docetaxel with trastuzumab (EC-TH) verses six cycles of paclitaxel combined with carboplatin and trastuzumab (PCbH); both followed by 1 year adjuvant trastuzumab. After pertuzumab became legally available in China, participants of PANSY-2 may choose to receive trastuzumab and pertuzumab dual targeted therapy, thus comparing the efficacy and safety of four cycles of epirubicin combined with cyclophosphamide followed by four cycles of docetaxel with trastuzumab and pertuzumab (EC-THP) verses six cycles of paclitaxel combined with carboplatin, trastuzumab and pertuzumab (PCbHP); both followed by 1 year adjuvant trastuzumab and pertuzumab. With the inclusion of pertuzumab in China's medical insurance in January 2020, study protocols were revised to include dual targeted therapy for HER2-positive participants.
Interventions
DRUGPaclitaxel
paclitaxel 80 mg/m\^2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.
DRUGCarboplatin
carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.
DRUGEpirubicin
epirubicin 90 mg/m\^2 ivgtt d1, 21 days per cycle, 4 cycles.
DRUGCyclophosphamide
cyclophosphamide 600 mg/m\^2 iv d1, 21 days per cycle, 4 cycles.
DRUGTrastuzumab
trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle with chemotherapy; or trastuzumab 2 mg/kg (loading dose 4mg/kg, w1) ivgtt d1, d8, d15, d22, 28 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks).
DRUGPertuzumab
pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant pertuzumab (420mg ivgtt every 3 weeks).
DRUGDocetaxel
docetaxel 100 mg/m\^2 ivgtt d1, 21 days per cycle, 4 cycles.
Sponsors
Fudan University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
Open label
Intervention model description
PANSY-1: Arm 1: EC-T: 4 cycles of EC (epirubicin + cyclophosphamide), followed by 4 cycles of T (docetaxel) . Arm 2: PCb: 6 cycles of weekly PCb (paclitaxel + carboplatin). PANSY-2: Arm 1: EC-TH(P): 4 cycles of EC (epirubicin + cyclophosphamide), followed by 4 cycles of TH TH(P) (docetaxel + trastuzumab, with pertuzumab for participants receiving dual-targeted therapy). After completing chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab, with pertuzumab for participants receiving dual-targeted therapy. Arm 2: PCbH(P): 6 cycles of weekly PCbH(P) (paclitaxel + carboplatin + trastuzumab, with pertuzumab for participants receiving dual-targeted therapy. After completing chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab, with pertuzumab for participants receiving dual-targeted therapy.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Female patients aged 18-70 years old; 2. Histologically confirmed unilateral invasive breast cancer (regardless of pathological type) 3. Operable breast cancer at first diagnosis, without any absolute surgical contraindication. 4. No gross nor microscopic residual tumor after surgery. 5. HER2-positive with ≥ 1 positive axillary lymph node; or estrogen receptor (ER) and/or progesterone receptor (PR)-positive and HER2-negative with ≥ 4 positive axillary lymph node. HER2-positive is defined as an immunohistochemistry (IHC) status of 3+, or a positive in situ hybridization (Fluorescence in situ hybridization (FISH), Chromogenic in situ hybridization (CISH)) test. ER-positive is defined as immunohistochemistry showing that ≥ 1% of tumor cells were ER positive. PR-positive is defined as immunohistochemistry showing that ≥ 1% of tumor cells were PR positive. 6. Preoperative examination found no evidence of metastasis in clinical examination nor imaging examination. 7. No peripheral neuropathy. 8. Karnofsky score \> 70. 9. Good postoperative recovery, at least 1 week has passed since most recent surgery. 10. Has adequate bone marrow function: leukocyte count \> 4x10ˆ9 / L, absolute neutrophil count \> 2x10ˆ9 /L; platelet count \> 100x10ˆ9 /L, hemoglobin \> 9g/dL. 11. Has adequate liver function: alanine aminotransferase (ALT) \< 1.5×upper limit of normal (ULN), aspartate aminotransferase (AST) \< 1.5×ULN, alkaline phosphatase (AKP) \< 2.5×ULN, total bilirubin (TBIL) \< 1.5×ULN. 12. Has adequate kidney function: serum creatinine \< 1.5×ULN. 13. Contraception during treatment for women of childbearing age. 14. Has adequate cardiac function: echocardiography showed left ventricular ejection fraction (LVEF) \> 50%. 15. Participants voluntarily joined the study, has signed informed consent before any trial related activities are conducted, has good compliance and has agreed to follow-up.
Exclusion criteria
1. Has received previous chemotherapy for late stage disease. 2. Has bilateral breast cancer or bilateral carcinoma in situ. 3. Has metastatic (Stage 4) breast cancer. 4. Has clinical T4 lesion (UICC1987) (with skin involvement, mass adhesion and fixation, and inflammatory breast cancer). 5. Has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy or endocrine therapy). 6. Has previous history of additional malignancy(with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ), including contralateral breast cancer. 7. Is already participating in another clinical trial. 8. Has severe systemic disease and/or uncontrolled infection. 9. Has insufficient cardiac function: echocardiography showed LVEF\< 50%. 10. Has suffered from severe cardiovascular and cerebrovascular diseases disease within the 6 months previous of randomization (such as unstable angina, chronic heart failure, uncontrolled hypertension with blood pressure\>150/90 mmHg, myocardial infarction, or cerebrovascular accident. 11. Has known allergy to chemotherapy drugs used in this study. 12. Is pregnant, is breast feeding, or is a woman of childbearing age who cannot practice effective contraceptives during treatment and until 8 weeks after the end of treatment. 13. Has entered the study, but pre-treatment examination showed a positive pregnancy test. 14. Has a history of mental disorders, cognitive impairment, inability to understand the study protocol and side effects, inability to complete the study protocol and follow-up workers (systematic evaluation is required before the patient is enrolled into the study), or is without independent civil capacity. 15. The researchers judged patients to be unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease free survival | 5 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Invasive Disease Free Survival | 5 years | — |
| Distant Disease Free Survival | 5 years | — |
| Overall Survival | 5 years | — |
| Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v4.0 | 5 years | Graded according to Common Terminology Criteria for Adverse Events (CTC-AE) 4.0 according to CTC-AE 4.0 |
Countries
China
Outcome results
None listed